TYPE 2 DIABETES MELLITUS Review of Clinical Practice Guidelines WEEK 1: Diagnosis and Evaluation UHN AIMGP CLINIC SEMINAR SERIES 2007 Updated by Dr. K.

Slides:



Advertisements
Similar presentations
Standards of Medical Care in Diabetes—2011
Advertisements

Standards of Medical Care in Diabetes—2012
Diabetes Self Management Laura Wintersteen-Arleth, MN, RN,CDE
1 Type 1 Diabetes Mellitus Treatment. 2 Goals of T1DM Management Utilize intensive therapy aimed at near-normal BG and A1C levels Prevent diabetic ketoacidosis.
Chapter 06 6 Diabetes Albright C H A P T E R. Definition Diabetes mellitus –A group of metabolic diseases –Characterized by inability to produce sufficient.
1 Prediabetes Screening and Monitoring. 2 Prediabetes Epidemiologic evidence suggests that the complications of T2DM begin early in the progression from.
Diabetes Care Summary of Revisions for the 2014 Clinical Practice Recommendations Copied from:
Screening for Type 1 and Type 2 Diabetes Chapter 4 Jean-Marie Ekoé, Zubin Punthakee, Thomas Ransom, Ally PH Prebtani, Ron Goldenberg Canadian Diabetes.
Glucose Tolerance Test Diabetes Mellitus Dr. David Gee FCSN Nutrition Assessment Laboratory.
Diabetes in Pregnancy Screening.
DR. TARIK Y. ZAMZAMI MD, CABOG, FICS ASSOCIATE PROFESSOR CONSULTANT OB/GYN
Al-Fada AA & Bin Abdulrahman KA, King Saud University, Riyadh, Saudi Arabia Assessment of Care for Type 2 Diabetic Patients at the PHC Clinics of a Referral.
A medical test to determine the ability of an individual to maintain HOMEOSTASIS of Blood Glucose The most commonly performed version of the Test (OGTT)
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Diagnosis of Type 2 Diabetes 1. Diagnostic Criteria for Prediabetes and Diabetes in Nonpregnant Adults 2 NormalHigh Risk for DiabetesDiabetes FPG
The Diagnosis of Diabetes Mellitus
COMMON LIFESTYLE DISEASES
Screening for Diabetes in Pregnancy 1. Gestational Diabetes Mellitus Screening GDM, gestational diabetes mellitus. Handelsman YH, et al. Endocr Pract.
Diabetic Nephropathy Case Presentations. UA (Urine Dipstick) Use as an initial screen for all patients Negative to trace proteinuria requires further.
Diabetes Mellitus Dr. Meg-angela Christi Amores. Diabetes Mellitus refers to a group of common metabolic disorders that share the phenotype of hyperglycemia.
1. DIABETIC NEPHROPATHY Dr. Shahrzad Shahidi 2 CLASSIFICATION 1. Type 1 (due to b-cell destruction, usually leading to absolute insulin deficiency) 2.
Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.
TYPE 2 DIABETES MELLITUS Asma Jafri, MD July 22, 2004.
Obesity and Type 2 Diabetes in children and adolescents Eva Tsalikian M.D. Stead family Department of Pediatrics Pediatric Endocrinology and Diabetes April.
Adult Medical-Surgical Nursing
Criteria for Diagnosis of DM * Testing must be repeated on separate day. FPG is the preferred test ** Symptoms of DM IFG = Impaired fasting glucose IGT.
Standard 3: Care Management a.) Guidelines for important conditions.
DIABETES 1 The Value of Screening: HbA1c as a Diagnostic Tool David Kendall, MD Chief Scientific and Medical Officer American Diabetes.
Diabetes Mellitus Ibrahim Sales, Pharm.D. Assistant Professor of Clinical Pharmacy King Saud University
CARE OF PATIENTS WITH DIABETES MELLITUS JANNA WICKHAM RN MSN LSSC FALL 2013 Chapter 20.
Chapter 24 Chapter 24 Exercise Management.  Diabetes is a chronic metabolic disease characterized by an absolute or relative deficiency of insulin that.
Nursing Care of Clients with Diabetes Mellitus.
Epidemiology of Diabetes Mellitus by Santi Martini Departemen of Epidemiology Faculty of Public Health University of Airlangga.
Assessing the patient Exercise and Type 1 Diabetes 2nd National conference NEC, 15 May 2015.
PRE-EXISTING DIABETES AND PREGNANCY 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
CFRD GUIDELINES UPDATE Dr Nigel Paterson, respirologist Tracy Gooyers, nurse case manager Pat Leggatt, dietitian.
Type 2 Diabetes- Treatment Toolbox by: Karen L. Staples, FNP, ACNP Where Do I Start?
What the GP Should Know about Diabetes Mellitus Dr. Muhieddin Omar.
Diabetes: The Modern Epidemic Roy Buchinsky, MD Director of Wellness.
Standards of Medical Care for Patients with Diabetes Mellitus John Guzek, MD March 2003.
DIABETES MELLITUS IN CHILDREN: CLINICAL FEATURES, DIAGNOSTICS AND TREATMENT Prof. H.A. Pavlyshyn.
Diabetes Mellitus Overview. Definition Disease of abnormal carbohydrate metabolism characterized by hyperglycemia Caused by: –Impairment in insulin secretion.
TYPE 2 DIABETES MELLITUS REVIEW OF Clinical Practice Guidelines WEEK 2: Therapy UHN AIMGP CLINIC SEMINAR SERIES 2007 Updates Dr. K. Tzanetos WEEK 2: Therapy.
GDM-DEFINITION Gestational Diabetes Mellitus (GDM) is defined as ‘carbohydrate intolerance with recognition or onset during pregnancy’, irrespective of.
PREVELANCE OF COMPLICATIONS OF DIABETES MELLITUS IN EGYPT Prof Morsi Arab University of Alexandria.
Screening for Type 1 & Type 2 Diabetes Key Messages In the absence of evidence for interventions to prevent or delay type 1 diabetes, screening for type.
Clinical Practice Glycemic Management of Type 2 Diabetes Mellitus Faramarz Ismail-Beigi, M.D., Ph.D. Dr.kalantar N Engl J Med Volume 366(14):
Diabetes mellitus “ Basic approach” Dr Sajith.V.S MBBS,MD (Gen Med )
Prince Sattam Bin AbdulAziz University College Of Pharmacy Professor Mohammad Abd- elmotaal Mohammad Ruhal Ain, R Ph, PGDPRA, M Pharm Diabetes Mellitus.
 Provide a high level overview of diabetes head to toe.  Discuss the importance of keeping A1Cs under 8.  Identify ways to prevent long-term complications.
Diabetes – Diagnosis and assessment
Diabetes mellitus By Dr. Mansour Alzahrani. I. CLASSIFICATION AND DIAGNOSIS.
Diabetes. Objectives: Diabetes Mellitus (DM) Discuss the prevalence of diabetes in the U.S. Contrast the main types of diabetes. Describe the classic.
GO! Diabetes Residency Train the Trainer Program.
OPD follow up 1. General P/E Blood pressure Sites of insulin injection Deep tendon reflex 2.
Acute Infections and Insulin Requirements In pre-diabetic individuals acute infections may induce a temporary state of diabetes requiring short-term insulin.
Dr Sheetal Saggar GP.  Bolton Diabetic Centre ◦ Consultants (4) ◦ Specialist Nurses (8) ◦ Podiatry ◦ Dietetics  General Practice ◦ Structure of diabetic.
A two stage screening process – the pre-diabetes pathway.
DIABETES CASE PRESENTATIONS 1 st - diagnosis. Case 1 Male, 24 yrs old Male, 24 yrs old Presents in the ER for nausea, vomiting, abdominal pain, shortness.
Copyright © 2016, 2013, 2010, 2006, 2002 by Saunders, an imprint of Elsevier Inc. Chapter 64-Iggy Pg Care of Patients with Diabetes Mellitus.
Prevention, Management and Diagnosis of Diabetes in Primary Care
Screening for Diabetes in Pregnancy
Diabetes Mellitus Cases
Care of Patients with Diabetes Mellitus
Diabetes Mellitus.
Screening and Monitoring
Screening for Diabetes in Pregnancy
Prevention, Management and Diagnosis of Diabetes in Primary Care
Diabetes: Microvascular Complications and Foot Care
Diabetes.
Presentation transcript:

TYPE 2 DIABETES MELLITUS Review of Clinical Practice Guidelines WEEK 1: Diagnosis and Evaluation UHN AIMGP CLINIC SEMINAR SERIES 2007 Updated by Dr. K. Tzanetos WEEK 1: Diagnosis and Evaluation UHN AIMGP CLINIC SEMINAR SERIES 2007 Updated by Dr. K. Tzanetos

TYPE 2 DIABETES MELLITUS Review of Clinical Practice Guidelines Canadian Diabetes Association (CDA): 2003 Clinical Practice Guidelines for the Prevention and Management of diabetes in Canada. Can J Diabetes 2003; 27 (Suppl 2). Can J Diabetes 2003; 27 (Suppl 2). American Diabetes Association (ADA): Clinical Practice Recommendations Diabetes Care 2004; 27 (Suppl 1). Diabetes Care 2004; 27 (Suppl 1). Canadian Diabetes Association (CDA): 2003 Clinical Practice Guidelines for the Prevention and Management of diabetes in Canada. Can J Diabetes 2003; 27 (Suppl 2). Can J Diabetes 2003; 27 (Suppl 2). American Diabetes Association (ADA): Clinical Practice Recommendations Diabetes Care 2004; 27 (Suppl 1). Diabetes Care 2004; 27 (Suppl 1).

TYPE 2 DIABETES MELLITUS Objectives: 1) Examine diagnostic criteria for type 2 diabetes 2) Discuss screening recommendations for type 2 diabetes 3) Explore the suggested evaluation for first visit 4) Appreciate the importance of follow-up 5) Identify specific disease complications - retinopathy/nephropathy/foot ulcerations Objectives: 1) Examine diagnostic criteria for type 2 diabetes 2) Discuss screening recommendations for type 2 diabetes 3) Explore the suggested evaluation for first visit 4) Appreciate the importance of follow-up 5) Identify specific disease complications - retinopathy/nephropathy/foot ulcerations

CASE: Mrs. X is a 58 year old woman referred to the AIMGP clinic by her GP with a random glucose of 12.0 mmol/L. She feels well with no complaints and this testing was done as a part of her routine blood work. Does she have diabetes ? Does she have diabetes ? What further testing could help you to decide? What further testing could help you to decide?CASE: Mrs. X is a 58 year old woman referred to the AIMGP clinic by her GP with a random glucose of 12.0 mmol/L. She feels well with no complaints and this testing was done as a part of her routine blood work. Does she have diabetes ? Does she have diabetes ? What further testing could help you to decide? What further testing could help you to decide? DIABETES MELLITUS Take a minute to discuss…

CASE: Mrs. X. Does she have diabetes? Does she have diabetes? Likely! BUT you must do further tests. Likely! BUT you must do further tests. Further testing needed…2 confirmatory laboratory glucose tests (FBG, random PG or 2hr 75g OGTT) on separate days in the absence of unequivocal hyperglycemia accompanied by an acute metabolic decompensation. Further testing needed…2 confirmatory laboratory glucose tests (FBG, random PG or 2hr 75g OGTT) on separate days in the absence of unequivocal hyperglycemia accompanied by an acute metabolic decompensation. CASE: Mrs. X. Does she have diabetes? Does she have diabetes? Likely! BUT you must do further tests. Likely! BUT you must do further tests. Further testing needed…2 confirmatory laboratory glucose tests (FBG, random PG or 2hr 75g OGTT) on separate days in the absence of unequivocal hyperglycemia accompanied by an acute metabolic decompensation. Further testing needed…2 confirmatory laboratory glucose tests (FBG, random PG or 2hr 75g OGTT) on separate days in the absence of unequivocal hyperglycemia accompanied by an acute metabolic decompensation. DIABETES MELLITUS Diagnostic Criteria for Type 2 DM

Random PG ≥ 11.1mmol/L* and symptoms of diabetes OR Fasting plasma glucose (FPG) ≥ 7.0 mmol/L † OR 2h PG in a 75-g oral glucose tolerance test (OGTT) ≥ 11.1 mmol/L * Symptoms include fatigue, polyuria, polydipsia and weight loss † Fasting is defined as no caloric intake for at least 8 h Random PG ≥ 11.1mmol/L* and symptoms of diabetes OR Fasting plasma glucose (FPG) ≥ 7.0 mmol/L † OR 2h PG in a 75-g oral glucose tolerance test (OGTT) ≥ 11.1 mmol/L * Symptoms include fatigue, polyuria, polydipsia and weight loss † Fasting is defined as no caloric intake for at least 8 h DIABETES MELLITUS Diagnostic Criteria for Type 2 DM

Glucose levels (mmol/L) for diagnosis: DIABETES MELLITUS Diagnostic Criteria for Type 2 DM FPG 2 h PG in a 75- g OGTT IFG NA IFG (isolated) and < 7.8 IGT (isolated) < 6.1 and IFG and IGT and Diabetes ≥ 7.0 or ≥ 11.1

BACK TO THE CASE: Mrs. X is a Caucasian female who has no other PMHx. Her family history is negative. Should Mrs. X. have been screened before now for type 2 diabetes? By what method? What high risk groups should undergo more frequent or earlier screening? BACK TO THE CASE: Mrs. X is a Caucasian female who has no other PMHx. Her family history is negative. Should Mrs. X. have been screened before now for type 2 diabetes? By what method? What high risk groups should undergo more frequent or earlier screening? DIABETES MELLITUS Take a minute to discuss…

All individuals should be evaluated annually for DM2 risk (demographic/clinical criteria) All individuals should be evaluated annually for DM2 risk (demographic/clinical criteria) In persons 40 yrs of age screening for DM2 using a FPG should be performed every 3 yrs In persons 40 yrs of age screening for DM2 using a FPG should be performed every 3 yrs More frequent and/or earlier screening should be considered in ‘high risk’ groups More frequent and/or earlier screening should be considered in ‘high risk’ groups All individuals should be evaluated annually for DM2 risk (demographic/clinical criteria) All individuals should be evaluated annually for DM2 risk (demographic/clinical criteria) In persons 40 yrs of age screening for DM2 using a FPG should be performed every 3 yrs In persons 40 yrs of age screening for DM2 using a FPG should be performed every 3 yrs More frequent and/or earlier screening should be considered in ‘high risk’ groups More frequent and/or earlier screening should be considered in ‘high risk’ groups DIABETES MELLITUS 3) Screening for Type 2 DM

Risk factors for Type 2 DM (CDA) Risk factors for Type 2 DM (CDA) First-degree relative with diabetes First-degree relative with diabetes Member of high-risk population (e.g. persons of Aboriginal, Hispanic, S. African, Asian or S. Asian descent) Member of high-risk population (e.g. persons of Aboriginal, Hispanic, S. African, Asian or S. Asian descent) History of IGT or IFG History of IGT or IFG Presence of complications of DM Presence of complications of DM Vascular disease (**assoc. with the metabolic synD) Vascular disease (**assoc. with the metabolic synD) History of GDM History of GDM Risk factors for Type 2 DM (CDA) Risk factors for Type 2 DM (CDA) First-degree relative with diabetes First-degree relative with diabetes Member of high-risk population (e.g. persons of Aboriginal, Hispanic, S. African, Asian or S. Asian descent) Member of high-risk population (e.g. persons of Aboriginal, Hispanic, S. African, Asian or S. Asian descent) History of IGT or IFG History of IGT or IFG Presence of complications of DM Presence of complications of DM Vascular disease (**assoc. with the metabolic synD) Vascular disease (**assoc. with the metabolic synD) History of GDM History of GDM DIABETES MELLITUS 3) Screening for Type 2 DM

Risk factors for Type 2 DM (CDA) cont’ Risk factors for Type 2 DM (CDA) cont’ History of macrosomal infant History of macrosomal infant HTN (**) HTN (**) Dyslipidemia (**) Dyslipidemia (**) Overweight (**) Overweight (**) PCOS (**) PCOS (**) Acanthosis nigricans (**) Acanthosis nigricans (**) Schizophrenia (incidence 3X higher than the gen. population) Schizophrenia (incidence 3X higher than the gen. population) Risk factors for Type 2 DM (CDA) cont’ Risk factors for Type 2 DM (CDA) cont’ History of macrosomal infant History of macrosomal infant HTN (**) HTN (**) Dyslipidemia (**) Dyslipidemia (**) Overweight (**) Overweight (**) PCOS (**) PCOS (**) Acanthosis nigricans (**) Acanthosis nigricans (**) Schizophrenia (incidence 3X higher than the gen. population) Schizophrenia (incidence 3X higher than the gen. population) DIABETES MELLITUS 3) Screening for Type 2 DM

CDA guidelines mandate yearly screening in patients with: CDA guidelines mandate yearly screening in patients with: Hx of IFG or IGT Hx of IFG or IGT Presence of complications associated with diabetes Presence of complications associated with diabetes Hx of gestational diabetes or macrosomic infant (>4kg) Hx of gestational diabetes or macrosomic infant (>4kg) Presence of HTN or CAD Presence of HTN or CAD Screening Method Screening Method FPG (universal recommendation) FPG (universal recommendation) 2 h PG OGTT if FPG not diagnostic 2 h PG OGTT if FPG not diagnostic Lack of standardization of the HBA1C test precludes its use for diagnosis Lack of standardization of the HBA1C test precludes its use for diagnosis CDA guidelines mandate yearly screening in patients with: CDA guidelines mandate yearly screening in patients with: Hx of IFG or IGT Hx of IFG or IGT Presence of complications associated with diabetes Presence of complications associated with diabetes Hx of gestational diabetes or macrosomic infant (>4kg) Hx of gestational diabetes or macrosomic infant (>4kg) Presence of HTN or CAD Presence of HTN or CAD Screening Method Screening Method FPG (universal recommendation) FPG (universal recommendation) 2 h PG OGTT if FPG not diagnostic 2 h PG OGTT if FPG not diagnostic Lack of standardization of the HBA1C test precludes its use for diagnosis Lack of standardization of the HBA1C test precludes its use for diagnosis DIABETES MELLITUS 3) Screening for Type 2 DM

CASE: Assume that you have taken a thorough medical history from Mrs. X that has included symptoms of hyperglycemia, symptoms of macrovascular and microvascular complications, nutritional details, and medical co-morbidities. Assume that you have taken a thorough medical history from Mrs. X that has included symptoms of hyperglycemia, symptoms of macrovascular and microvascular complications, nutritional details, and medical co-morbidities. What would you now like to emphasize on Mrs. X.’s physical examination during her initial visit? What would you now like to emphasize on Mrs. X.’s physical examination during her initial visit?CASE: Assume that you have taken a thorough medical history from Mrs. X that has included symptoms of hyperglycemia, symptoms of macrovascular and microvascular complications, nutritional details, and medical co-morbidities. Assume that you have taken a thorough medical history from Mrs. X that has included symptoms of hyperglycemia, symptoms of macrovascular and microvascular complications, nutritional details, and medical co-morbidities. What would you now like to emphasize on Mrs. X.’s physical examination during her initial visit? What would you now like to emphasize on Mrs. X.’s physical examination during her initial visit? DIABETES MELLITUS Take a minute to discuss…

PE in a patient with DM: PE in a patient with DM: General (height, weight, BMI, postural BP, HR) General (height, weight, BMI, postural BP, HR) H & N (Pupils, EOMs, Lens opacities, fundi, oral hygiene and dental caries, thyroid) H & N (Pupils, EOMs, Lens opacities, fundi, oral hygiene and dental caries, thyroid) CVS (signs of HTN, CHF, CAD; pulses, bruits, other signs of PVD) CVS (signs of HTN, CHF, CAD; pulses, bruits, other signs of PVD) Abdomen (hepatomegaly) Abdomen (hepatomegaly) GU (r/o fungal infections, bladder distension) GU (r/o fungal infections, bladder distension) MSK (foot inspection, colour, temperature, arthropathy) MSK (foot inspection, colour, temperature, arthropathy) Neuro (dysesthesiae, change in proprioception, vibration, light touch [monofilament], reflexes, autonomic nervous system) Neuro (dysesthesiae, change in proprioception, vibration, light touch [monofilament], reflexes, autonomic nervous system) Skin (infections, dyslipidemias, ulcers, trauma, injection sites) Skin (infections, dyslipidemias, ulcers, trauma, injection sites) PE in a patient with DM: PE in a patient with DM: General (height, weight, BMI, postural BP, HR) General (height, weight, BMI, postural BP, HR) H & N (Pupils, EOMs, Lens opacities, fundi, oral hygiene and dental caries, thyroid) H & N (Pupils, EOMs, Lens opacities, fundi, oral hygiene and dental caries, thyroid) CVS (signs of HTN, CHF, CAD; pulses, bruits, other signs of PVD) CVS (signs of HTN, CHF, CAD; pulses, bruits, other signs of PVD) Abdomen (hepatomegaly) Abdomen (hepatomegaly) GU (r/o fungal infections, bladder distension) GU (r/o fungal infections, bladder distension) MSK (foot inspection, colour, temperature, arthropathy) MSK (foot inspection, colour, temperature, arthropathy) Neuro (dysesthesiae, change in proprioception, vibration, light touch [monofilament], reflexes, autonomic nervous system) Neuro (dysesthesiae, change in proprioception, vibration, light touch [monofilament], reflexes, autonomic nervous system) Skin (infections, dyslipidemias, ulcers, trauma, injection sites) Skin (infections, dyslipidemias, ulcers, trauma, injection sites) DIABETES MELLITUS Evaluation at first visit

CASE: What laboratory tests would you like to obtain on or shortly after Mrs. X.’s initial visit ? What laboratory tests would you like to obtain on or shortly after Mrs. X.’s initial visit ?CASE: DIABETES MELLITUS Take a minute to discuss…

What laboratory tests would you like to obtain on or shortly after Mrs. X.’s initial visit (ADA)? What laboratory tests would you like to obtain on or shortly after Mrs. X.’s initial visit (ADA)? FPG (optional), HbA1c FPG (optional), HbA1c Fasting lipid profile Fasting lipid profile Serum creatinine, Urinalysis Serum creatinine, Urinalysis Test for microalbuminuria (type 1 diabetic patients after at least 5 years and in all patients with type 2 diabetes at diagnosis) Test for microalbuminuria (type 1 diabetic patients after at least 5 years and in all patients with type 2 diabetes at diagnosis) Urine culture (if indicated) Urine culture (if indicated) Thyroid-stimulating hormone (TSH) in all type 1 diabetic patients; in type 2 if clinically indicated Thyroid-stimulating hormone (TSH) in all type 1 diabetic patients; in type 2 if clinically indicated ECG ECG What laboratory tests would you like to obtain on or shortly after Mrs. X.’s initial visit (ADA)? What laboratory tests would you like to obtain on or shortly after Mrs. X.’s initial visit (ADA)? FPG (optional), HbA1c FPG (optional), HbA1c Fasting lipid profile Fasting lipid profile Serum creatinine, Urinalysis Serum creatinine, Urinalysis Test for microalbuminuria (type 1 diabetic patients after at least 5 years and in all patients with type 2 diabetes at diagnosis) Test for microalbuminuria (type 1 diabetic patients after at least 5 years and in all patients with type 2 diabetes at diagnosis) Urine culture (if indicated) Urine culture (if indicated) Thyroid-stimulating hormone (TSH) in all type 1 diabetic patients; in type 2 if clinically indicated Thyroid-stimulating hormone (TSH) in all type 1 diabetic patients; in type 2 if clinically indicated ECG ECG DIABETES MELLITUS Evaluation at first visit

CASE: How frequently should patients like Mrs. X be followed after the initial visit? How frequently should patients like Mrs. X be followed after the initial visit? Consider the following patient circumstances: Consider the following patient circumstances: Diabetes is Diet controlled Diabetes is Diet controlled Patient on oral hypoglyemics (at initiation, when titrating, on maintenance dosing) Patient on oral hypoglyemics (at initiation, when titrating, on maintenance dosing) Patient on insulin (at initiation, when titrating, on maintenance dosing) Patient on insulin (at initiation, when titrating, on maintenance dosing) For routine visits if they are meeting goals For routine visits if they are meeting goals For routine visits if they are not meeting goals For routine visits if they are not meeting goalsCASE: How frequently should patients like Mrs. X be followed after the initial visit? How frequently should patients like Mrs. X be followed after the initial visit? Consider the following patient circumstances: Consider the following patient circumstances: Diabetes is Diet controlled Diabetes is Diet controlled Patient on oral hypoglyemics (at initiation, when titrating, on maintenance dosing) Patient on oral hypoglyemics (at initiation, when titrating, on maintenance dosing) Patient on insulin (at initiation, when titrating, on maintenance dosing) Patient on insulin (at initiation, when titrating, on maintenance dosing) For routine visits if they are meeting goals For routine visits if they are meeting goals For routine visits if they are not meeting goals For routine visits if they are not meeting goals DIABETES MELLITUS Take a minute to discuss…

Follow-up Visit Frequency (ADA)? Follow-up Visit Frequency (ADA)? Daily for initiation of insulin or change in regimen Daily for initiation of insulin or change in regimen Weekly for initiation of oral hypoglycemic agents or change in regimen Weekly for initiation of oral hypoglycemic agents or change in regimen (Are we meeting, or do we need to meet, these guidelines in AIMGP?) Routine diabetes visits: Routine diabetes visits: Quarterly for patients who are not meeting goals Quarterly for patients who are not meeting goals (Is this frequent enough?) (Is this frequent enough?) Semi-annually for patients with well- controlled diabetes Semi-annually for patients with well- controlled diabetes Follow-up Visit Frequency (ADA)? Follow-up Visit Frequency (ADA)? Daily for initiation of insulin or change in regimen Daily for initiation of insulin or change in regimen Weekly for initiation of oral hypoglycemic agents or change in regimen Weekly for initiation of oral hypoglycemic agents or change in regimen (Are we meeting, or do we need to meet, these guidelines in AIMGP?) Routine diabetes visits: Routine diabetes visits: Quarterly for patients who are not meeting goals Quarterly for patients who are not meeting goals (Is this frequent enough?) (Is this frequent enough?) Semi-annually for patients with well- controlled diabetes Semi-annually for patients with well- controlled diabetes DIABETES MELLITUS Evaluation in follow-up

CASE: What historical information will you gather on Mrs. X’s follow-up visits? What historical information will you gather on Mrs. X’s follow-up visits? What would you like to emphasize on Mrs. X.’s physical examination during her follow-up visits? What would you like to emphasize on Mrs. X.’s physical examination during her follow-up visits? Include discussion on appropriate frequency of various maneuvers Include discussion on appropriate frequency of various maneuvers What laboratory tests would you like to obtain on or shortly after Mrs. X.’s follow-up visits? What laboratory tests would you like to obtain on or shortly after Mrs. X.’s follow-up visits? Include discussion on appropriate frequency of various tests Include discussion on appropriate frequency of various testsCASE: What historical information will you gather on Mrs. X’s follow-up visits? What historical information will you gather on Mrs. X’s follow-up visits? What would you like to emphasize on Mrs. X.’s physical examination during her follow-up visits? What would you like to emphasize on Mrs. X.’s physical examination during her follow-up visits? Include discussion on appropriate frequency of various maneuvers Include discussion on appropriate frequency of various maneuvers What laboratory tests would you like to obtain on or shortly after Mrs. X.’s follow-up visits? What laboratory tests would you like to obtain on or shortly after Mrs. X.’s follow-up visits? Include discussion on appropriate frequency of various tests Include discussion on appropriate frequency of various tests DIABETES MELLITUS Take a minute to discuss…

DIABETES MELLITUS Evaluation in follow-up History taking on follow-up visits: History taking on follow-up visits: Treatment regimens (frequency of hyper/hypoglycemia, acute symptoms, self- monitoring BG results, pt regimen adjustments, adherence problems) Treatment regimens (frequency of hyper/hypoglycemia, acute symptoms, self- monitoring BG results, pt regimen adjustments, adherence problems) Lifestyle changes Lifestyle changes Symptoms of chronic complications (including ensuring visits to opthomologist) Symptoms of chronic complications (including ensuring visits to opthomologist) Changes in co-morbidities Changes in co-morbidities Psychosocial issues Psychosocial issues Immunization status Immunization status History taking on follow-up visits: History taking on follow-up visits: Treatment regimens (frequency of hyper/hypoglycemia, acute symptoms, self- monitoring BG results, pt regimen adjustments, adherence problems) Treatment regimens (frequency of hyper/hypoglycemia, acute symptoms, self- monitoring BG results, pt regimen adjustments, adherence problems) Lifestyle changes Lifestyle changes Symptoms of chronic complications (including ensuring visits to opthomologist) Symptoms of chronic complications (including ensuring visits to opthomologist) Changes in co-morbidities Changes in co-morbidities Psychosocial issues Psychosocial issues Immunization status Immunization status

Type 2 diabetes: Type 2 diabetes: At time of diagnosis At time of diagnosis 1 year or less if retinopathy present 1 year or less if retinopathy present Every 1-2 yrs on advice of eye care professional if no evidence of retinopathy Every 1-2 yrs on advice of eye care professional if no evidence of retinopathy Type 2 diabetes: Type 2 diabetes: At time of diagnosis At time of diagnosis 1 year or less if retinopathy present 1 year or less if retinopathy present Every 1-2 yrs on advice of eye care professional if no evidence of retinopathy Every 1-2 yrs on advice of eye care professional if no evidence of retinopathy DIABETES MELLITUS A Note on Retinopathy: Opthomology Follow-up DIABETES MELLITUS A Note on Retinopathy: Opthomology Follow-up

Physical Examination at Follow-up Visits (ADA)? Physical Examination at Follow-up Visits (ADA)? At every regular diabetes visit: At every regular diabetes visit: Weight Weight BP BP Previous abnormalities on physical exam Previous abnormalities on physical exam Complete physical exam annually Complete physical exam annually Comprehensive foot examination annually and visual inspection at every visit (and shoes!!) Comprehensive foot examination annually and visual inspection at every visit (and shoes!!) Physical Examination at Follow-up Visits (ADA)? Physical Examination at Follow-up Visits (ADA)? At every regular diabetes visit: At every regular diabetes visit: Weight Weight BP BP Previous abnormalities on physical exam Previous abnormalities on physical exam Complete physical exam annually Complete physical exam annually Comprehensive foot examination annually and visual inspection at every visit (and shoes!!) Comprehensive foot examination annually and visual inspection at every visit (and shoes!!) DIABETES MELLITUS Evaluation in follow-up

Initial visit and annually thereafter IDENTIFY: Initial visit and annually thereafter IDENTIFY: Peripheral neuropathy (monofilament or vibration) Peripheral neuropathy (monofilament or vibration) Altered biomechanics (evidence of increased pressure - callus, erythema; limited joint mobility; bony deformity; or severe nail pathology - thick nails) Altered biomechanics (evidence of increased pressure - callus, erythema; limited joint mobility; bony deformity; or severe nail pathology - thick nails) Peripheral vascular disease (hx of claudication, pulse exam, skin exam) Peripheral vascular disease (hx of claudication, pulse exam, skin exam) History of ulcers or amputation History of ulcers or amputation The presence of any of these risk factors requires visualization of the patient’s feet at every subsequent visit The presence of any of these risk factors requires visualization of the patient’s feet at every subsequent visit Initial visit and annually thereafter IDENTIFY: Initial visit and annually thereafter IDENTIFY: Peripheral neuropathy (monofilament or vibration) Peripheral neuropathy (monofilament or vibration) Altered biomechanics (evidence of increased pressure - callus, erythema; limited joint mobility; bony deformity; or severe nail pathology - thick nails) Altered biomechanics (evidence of increased pressure - callus, erythema; limited joint mobility; bony deformity; or severe nail pathology - thick nails) Peripheral vascular disease (hx of claudication, pulse exam, skin exam) Peripheral vascular disease (hx of claudication, pulse exam, skin exam) History of ulcers or amputation History of ulcers or amputation The presence of any of these risk factors requires visualization of the patient’s feet at every subsequent visit The presence of any of these risk factors requires visualization of the patient’s feet at every subsequent visit DIABETES MELLITUS A Note on Foot Care

Laboratory tests at follow-up visits (ADA) Laboratory tests at follow-up visits (ADA) HbA1c HbA1c Quarterly if medications change or patient not meeting goals Quarterly if medications change or patient not meeting goals Semi-annually if stable Semi-annually if stable FPG (optional) FPG (optional) Fasting lipid profile annually, unless low risk Fasting lipid profile annually, unless low risk Urinary microalbumin measurement annually (if indicated) Urinary microalbumin measurement annually (if indicated) Laboratory tests at follow-up visits (ADA) Laboratory tests at follow-up visits (ADA) HbA1c HbA1c Quarterly if medications change or patient not meeting goals Quarterly if medications change or patient not meeting goals Semi-annually if stable Semi-annually if stable FPG (optional) FPG (optional) Fasting lipid profile annually, unless low risk Fasting lipid profile annually, unless low risk Urinary microalbumin measurement annually (if indicated) Urinary microalbumin measurement annually (if indicated) DIABETES MELLITUS Evaluation in follow-up

Annual screening with a random daytime urine albumin: creatinine ratio (ACR) Annual screening with a random daytime urine albumin: creatinine ratio (ACR) For values ≥ 2.8 for females and 2.0 for males the test should be repeated For values ≥ 2.8 for females and 2.0 for males the test should be repeated confirmed in 2 out of 3 measurements over 3 months confirmed in 2 out of 3 measurements over 3 months Uncertainty is clarified by 24h urine for protein Uncertainty is clarified by 24h urine for protein Microalbuminuria = mg of albumin/24hrs Microalbuminuria = mg of albumin/24hrs NB: If patients are dipstick positive, they will likely have macroalbuminuria NB: If patients are dipstick positive, they will likely have macroalbuminuria Annual screening with a random daytime urine albumin: creatinine ratio (ACR) Annual screening with a random daytime urine albumin: creatinine ratio (ACR) For values ≥ 2.8 for females and 2.0 for males the test should be repeated For values ≥ 2.8 for females and 2.0 for males the test should be repeated confirmed in 2 out of 3 measurements over 3 months confirmed in 2 out of 3 measurements over 3 months Uncertainty is clarified by 24h urine for protein Uncertainty is clarified by 24h urine for protein Microalbuminuria = mg of albumin/24hrs Microalbuminuria = mg of albumin/24hrs NB: If patients are dipstick positive, they will likely have macroalbuminuria NB: If patients are dipstick positive, they will likely have macroalbuminuria DIABETES MELLITUS A Note on Nephropathy: Screening

DIABETES MELLITUS UHN AIMGP CLINIC SUMMER SERIES 2007 Next week - Therapy of Type 2 DM Non-pharmacologic and pharmacologic DIABETES MELLITUS UHN AIMGP CLINIC SUMMER SERIES 2007 Next week - Therapy of Type 2 DM Non-pharmacologic and pharmacologic